Toll Free: 1-888-928-9744

Epilepsy - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 421 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Epilepsy - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Epilepsy - Pipeline Review, H2 2016', provides an overview of the Epilepsy pipeline landscape. 

The report provides comprehensive information on the therapeutics under development for Epilepsy, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Epilepsy and features dormant and discontinued projects. 

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Epilepsy
- The report reviews pipeline therapeutics for Epilepsy by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved Epilepsy therapeutics and enlists all their major and minor projects
- The report assesses Epilepsy therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news related to pipeline therapeutics for Epilepsy

Reasons To Buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand important and diverse types of therapeutics under development for Epilepsy
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Epilepsy pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
 Table of Contents
Table of Contents 2 Introduction 6 Epilepsy Overview 7 Therapeutics Development 8 Epilepsy - Therapeutics under Development by Companies 10 Epilepsy - Therapeutics under Investigation by Universities/Institutes 17 Epilepsy - Pipeline Products Glance 19 Epilepsy - Products under Development by Companies 23 Epilepsy - Products under Investigation by Universities/Institutes 33 Epilepsy - Companies Involved in Therapeutics Development 34 Epilepsy - Therapeutics Assessment 99 Drug Profiles 117 Epilepsy - Dormant Projects 379 Epilepsy - Discontinued Products 389 Epilepsy - Product Development Milestones 391 Appendix 404
List of Tables
Number of Products under Development for Epilepsy, H2 2016 24 Number of Products under Development for Epilepsy - Comparative Analysis, H2 2016 25 Number of Products under Development by Companies, H2 2016 27 Number of Products under Development by Companies, H2 2016 (Contd..1) 28 Number of Products under Development by Companies, H2 2016 (Contd..2) 29 Number of Products under Development by Companies, H2 2016 (Contd..3) 30 Number of Products under Development by Companies, H2 2016 (Contd..4) 31 Number of Products under Development by Companies, H2 2016 (Contd..5) 32 Number of Products under Investigation by Universities/Institutes, H2 2016 34 Comparative Analysis by Late Stage Development, H2 2016 35 Comparative Analysis by Clinical Stage Development, H2 2016 36 Comparative Analysis by Early Stage Development, H2 2016 37 Comparative Analysis by Unknown Stage Development, H2 2016 38 Products under Development by Companies, H2 2016 39 Products under Development by Companies, H2 2016 (Contd..1) 40 Products under Development by Companies, H2 2016 (Contd..2) 41 Products under Development by Companies, H2 2016 (Contd..3) 42 Products under Development by Companies, H2 2016 (Contd..4) 43 Products under Development by Companies, H2 2016 (Contd..5) 44 Products under Development by Companies, H2 2016 (Contd..6) 45 Products under Development by Companies, H2 2016 (Contd..7) 46 Products under Development by Companies, H2 2016 (Contd..8) 47 Products under Development by Companies, H2 2016 (Contd..9) 48 Products under Investigation by Universities/Institutes, H2 2016 49 Epilepsy - Pipeline by Adamas Pharmaceuticals, Inc., H2 2016 50 Epilepsy - Pipeline by Advicenne, H2 2016 51 Epilepsy - Pipeline by Aeolus Pharmaceuticals, Inc., H2 2016 52 Epilepsy - Pipeline by Aequus Pharmaceuticals Inc., H2 2016 53 Epilepsy - Pipeline by Aestus Therapeutics, Inc., H2 2016 54 Epilepsy - Pipeline by Alexza Pharmaceuticals, Inc., H2 2016 55 Epilepsy - Pipeline by Anavex Life Sciences Corp., H2 2016 56 Epilepsy - Pipeline by Asklepios BioPharmaceutical, Inc., H2 2016 57 Epilepsy - Pipeline by Astellas Pharma Inc., H2 2016 58 Epilepsy - Pipeline by Bial - Portela & Ca, S.A., H2 2016 59 Epilepsy - Pipeline by BioCrea GmbH, H2 2016 60 Epilepsy - Pipeline by Biogen Inc, H2 2016 61 Epilepsy - Pipeline by Bionomics Limited, H2 2016 62 Epilepsy - Pipeline by Biovista Inc., H2 2016 63 Epilepsy - Pipeline by Biscayne Pharmaceuticals, Inc., H2 2016 64 Epilepsy - Pipeline by Catalyst Pharmaceuticals, Inc., H2 2016 65 Epilepsy - Pipeline by D-Pharm Ltd., H2 2016 66 Epilepsy - Pipeline by Eisai Co., Ltd., H2 2016 67 Epilepsy - Pipeline by Glialogix, Inc., H2 2016 68 Epilepsy - Pipeline by Grifols, S.A., H2 2016 69 Epilepsy - Pipeline by GW Pharmaceuticals Plc, H2 2016 70 Epilepsy - Pipeline by H. Lundbeck A/S, H2 2016 71 Epilepsy - Pipeline by Hyundai Pharmaceutical Co., Ltd., H2 2016 72 Epilepsy - Pipeline by INSYS Therapeutics, Inc., H2 2016 73 Epilepsy - Pipeline by INVENT Pharmaceuticals, Inc., H2 2016 74 Epilepsy - Pipeline by Iproteos S.L., H2 2016 75 Epilepsy - Pipeline by Johnson & Johnson, H2 2016 76 Epilepsy - Pipeline by Knopp Biosciences LLC, H2 2016 77 Epilepsy - Pipeline by Lead Discovery Center GmbH, H2 2016 78 Epilepsy - Pipeline by Lipicard Technologies Limited, H2 2016 79 Epilepsy - Pipeline by Lotus Pharmaceutical Co., Ltd., H2 2016 80 Epilepsy - Pipeline by Marathon Pharmaceuticals, LLC, H2 2016 81 Epilepsy - Pipeline by Marinus Pharmaceuticals, Inc., H2 2016 82 Epilepsy - Pipeline by Mitochon Pharmaceuticals, Inc., H2 2016 83 Epilepsy - Pipeline by Neurelis, Inc., H2 2016 84 Epilepsy - Pipeline by Neurocrine Biosciences, Inc., H2 2016 85 Epilepsy - Pipeline by Neuron Biopharma SA, H2 2016 86 Epilepsy - Pipeline by Novartis AG, H2 2016 87 Epilepsy - Pipeline by OPKO Health, Inc., H2 2016 88 Epilepsy - Pipeline by Ovid Therapeutics Inc., H2 2016 89 Epilepsy - Pipeline by Pfizer Inc., H2 2016 90 Epilepsy - Pipeline by PharmatrophiX, Inc., H2 2016 91 Epilepsy - Pipeline by Promius Pharma, LLC, H2 2016 92 Epilepsy - Pipeline by PTC Therapeutics, Inc., H2 2016 93 Epilepsy - Pipeline by Retrophin Inc., H2 2016 94 Epilepsy - Pipeline by Sage Therapeutics, Inc., H2 2016 95 Epilepsy - Pipeline by Saniona AB, H2 2016 96 Epilepsy - Pipeline by SciFluor Life Sciences, LLC, H2 2016 97 Epilepsy - Pipeline by Shire Plc, H2 2016 98 Epilepsy - Pipeline by SK Biopharmaceuticals Co., Ltd., H2 2016 99 Epilepsy - Pipeline by Suda Ltd, H2 2016 100 Epilepsy - Pipeline by Sumitomo Dainippon Pharma Co., Ltd., H2 2016 101 Epilepsy - Pipeline by Takeda Pharmaceutical Company Limited, H2 2016 102 Epilepsy - Pipeline by Trillium Therapeutics Inc., H2 2016 103 Epilepsy - Pipeline by Turing Pharmaceuticals AG , H2 2016 104 Epilepsy - Pipeline by UCB S.A., H2 2016 105 Epilepsy - Pipeline by Ultragenyx Pharmaceutical Inc., H2 2016 106 Epilepsy - Pipeline by Upsher-Smith Laboratories, Inc., H2 2016 107 Epilepsy - Pipeline by Vichem Chemie Research Ltd., H2 2016 108 Epilepsy - Pipeline by VistaGen Therapeutics , Inc., H2 2016 109 Epilepsy - Pipeline by Vitality Biopharma Inc, H2 2016 110 Epilepsy - Pipeline by Xenon Pharmaceuticals Inc., H2 2016 111 Epilepsy - Pipeline by XERIS Pharmaceuticals, Inc., H2 2016 112 Epilepsy - Pipeline by Zogenix, Inc., H2 2016 113 Epilepsy - Pipeline by Zynerba Pharmaceuticals, Inc., H2 2016 114 Assessment by Monotherapy Products, H2 2016 115 Number of Products by Stage and Target, H2 2016 117 Number of Products by Stage and Mechanism of Action, H2 2016 123 Number of Products by Stage and Route of Administration, H2 2016 130 Number of Products by Stage and Molecule Type, H2 2016 132 Epilepsy - Dormant Projects, H2 2016 395 Epilepsy - Dormant Projects (Contd..1), H2 2016 396 Epilepsy - Dormant Projects (Contd..2), H2 2016 397 Epilepsy - Dormant Projects (Contd..3), H2 2016 398 Epilepsy - Dormant Projects (Contd..4), H2 2016 399 Epilepsy - Dormant Projects (Contd..5), H2 2016 400 Epilepsy - Dormant Projects (Contd..6), H2 2016 401 Epilepsy - Dormant Projects (Contd..7), H2 2016 402 Epilepsy - Dormant Projects (Contd..8), H2 2016 403 Epilepsy - Dormant Projects (Contd..9), H2 2016 404 Epilepsy - Discontinued Products, H2 2016 405 Epilepsy - Discontinued Products (Contd..1), H2 2016 406



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $2000
Multi User - US $4000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Quality assurance

A testimonial for service excellence represented in the form of BBB "A" Accreditation.

Information security

Your personal and confidential information is safe and secure.

verify